AZN GB0009895292

Report

Delayed London Stock Exchange - 11:35 2022-08-12 am EDT
10712.00	GBX		+1.96%

08/12	Seagen loses arbitration against Daiichi Sankyo over drug technology	RE
08/12	Seagen loses arbitration ruling against Daiichi Sankyo	RE
08/12	European Stocks Close Higher After UK GDP, Eurozone Industrial Production Data	MT

Company

Business Summary

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:

- product sales (97.7%). Net sales break down by treatment area between oncology (35.7%), cardiovascular, renal and metabolic diseases (21.9%), respiratory and autoimmune diseases (16.5%), and other (25.9%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);

- collaboration revenue (2.3%).

Net sales are distributed geographically as follows: the United Kingdom (8.7%), Continental Europe (20.9%), Americas (37.5%) and Africa/Asia/Australia (32.9%).

Number of employees : 83 100 people.

Sales per Business

	2020		2021		Delta
Oncology	8 461.00	40.8%	9 487.36	34.9%	+12.13%
Cardiovascular, Renal & Metabolism	5 533.57	26.7%	5 831.44	21.4%	+5.38%
Respiratory & Immunology	4 177.47	20.1%	4 387.39	16.1%	+5.03%
COVID-19	-	-	2 909.90	10.7%	-
Rare Disease	-	-	2 232.23	8.2%	-
Other Medicines	2 017.38	9.7%	1 721.07	6.3%	-14.69%
Collaboration	566.93	2.7%	636.95	2.3%	+12.35%
GBP in Million

Sales per region

	2020		2021		Delta
United States	6 983.25	33.6%	8 759.52	32.2%	+25.44%
China	4 168.11	20.1%	4 364.13	16%	+4.7%
Japan	2 001.79	9.6%	2 468.55	9.1%	+23.32%
United Kingdom	1 357.66	6.5%	2 359.48	8.7%	+73.79%
Other Asia, Africa and Australasia	1 196.24	5.8%	1 729.80	6.4%	+44.6%
Sweden	800.09	3.9%	1 688.35	6.2%	+111.02%
Other Rest of Europe	1 084.72	5.2%	1 417.14	5.2%	+30.65%
Germany	730.69	3.5%	1 080.49	4%	+47.87%
Other Americas	593.44	2.9%	874.72	3.2%	+47.4%
France	509.22	2.5%	665.31	2.4%	+30.65%
Canada	464.77	2.2%	561.33	2.1%	+20.78%
Spain	310.37	1.5%	420.27	1.5%	+35.41%
Italy	336.10	1.6%	419.54	1.5%	+24.83%
Australia	219.91	1.1%	397.73	1.5%	+80.86%
GBP in Million

Managers

Name	Title	Age	Since
Pascal Soriot	Chief Executive Officer & Executive Director	62	2012
Aradhana Sarin	Chief Financial Officer & Executive Director	47	2021
Menelas Pangalos	EVP-Biopharmaceuticals Research & Development	54	2019
Pam Cheng	Executive VP-Operations & Information Technology	50	2015
Henry Cremisi	Medical Director	-	-
Regina Danielson	SVP, Head-Research & Early Development	-	-
Katarina Ageborg	Chief Compliance Officer & EVP-Sustainability	-	2017
Jonathan Thomas Charles Slade	Group Treasurer	56	-
Adrian Charles Noel Kemp	Secretary	55	2009
Ruud Dobber, Dr.	Executive VP-Biopharmaceuticals Business	-	2019

Members of the board

Name	Title	Age	Since
Leif Johansson	Non-Executive Chairman	69	2012
Marcus Wallenberg	Independent Non-Executive Director	65	1999
Philip Arthur John Broadley	Senior Independent Non-Executive Director	60	2021
Nazneen Rahman, Dr.	Independent Non-Executive Director	-	2017
Sherilyn McCoy	Independent Non-Executive Director	62	2017
Deborah DiSanzo	Independent Non-Executive Director	61	2017
Tony Mok, Dr.	Independent Non-Executive Director	60	2019
Michel Demaré	Chairman-Designate	65	2022
Pascal Soriot	Chief Executive Officer & Executive Director	62	2012
Euan A. Ashley, Dr.	Non-Executive Director	-	2020

Equities

	Vote	Quantity	Free-Float		Company-owned shares		Total Float
Stock A	1	1,549,489,389	1,493,140,483	96.4%	0	0.0%	96.4%

Shareholders

Name	Equities	%
BlackRock Investment Management (UK) Ltd.	87,816,365	5.67%
Wellington Management Co. LLP	64,146,178	4.14%
Investor AB (Investment Company)	51,587,810	3.33%
The Vanguard Group, Inc.	48,125,000	3.11%
Capital Research & Management Co. (World Investors)	46,132,337	2.98%
Norges Bank Investment Management	30,921,000	2.00%
BlackRock Fund Advisors	27,770,415	1.79%
BlackRock Advisors (UK) Ltd.	21,488,979	1.39%
GQG Partners LLC	15,351,000	0.99%
SSgA Funds Management, Inc.	13,564,000	0.88%

Holdings

Name	Equities	%	Valuation
ASTRAZENECA PHARMA INDIA LIMITED (506820)	18,750,000	75.0%	641,912,438 USD
DIZAL JIANGSU PHARMACEUTICAL CO. LTD.	108,923,023	29.8%	435,086,480 USD
ADC THERAPEUTICS SA (ADCT)	4,011,215	5.22%	31,889,159 USD
CIRCASSIA GROUP PLC (CIR)	71,059,999	16.9%	29,773,429 USD
INNATE PHARMA (IPH)	7,485,500	9.39%	20,065,107 USD
PIERIS PHARMACEUTICALS, INC. (PIRS)	3,584,230	4.97%	6,702,510 USD
ENTASIS THERAPEUTICS HOLDINGS, INC.	2,164,855	4.52%	4,762,681 USD
PHASEBIO PHARMACEUTICALS, INC. (PHAS)	3,004,554	6.17%	1,802,732 USD
ARIDIS PHARMACEUTICALS, INC. (ARDS)	884,956	5.00%	973,452 USD

Markets and indexes

- Main Market

- FTSE 100 / FTSE 350, FTSE All-Share, FTSE Eurotop 100, Low Carbon 100 Europe, Nasdaq 100, NASDAQ OMX Nordic 120, OMX Nordic 40, OMX Stockholm 30, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200, Stoxx UK 50

Stock Exchange Codes


- Bloomberg Code :	AZN:LN
- Reuters Code :	AZN.L
- Datastream Code :

Company contact information

AstraZeneca PLC
Cambridge Biomedical Campus 1 Francis Crick Avenue
CB2 0AA Cambridge, Cambridgeshire

Phone : +44 (0)20 3749 5000
Fax : +44 (0)20 7604 8151
web site : https://www.astrazeneca.com/investor-relations.html

Brand Portfolio

In partnership with

Allbrands.markets

ACERTA PHARMA	ALEXION	ALEXION PHARMACEUTICALS	ARDEA BIOSCIENCES
ASTRAZENECA	ENOBIA PHARMA	FORXIGA	IMFINZI
LYNPARZA	PORTOLA PHARMACEUTICALS	SYNAGEVA BIOPHARMA	SYNTIMMUNE
TAGRISSO	TALIGEN THERAPEUTICS

More brands of AstraZeneca PLC

Analysis

Chasing green goals, corporations push car fleet managers toward EVs

ASTRAZENECA PLC